Rozerem DTC campaign to launch this summer

Share this article:
Takeda Pharmaceuticals North America is set to begin marketing its prescription insomnia drug, Rozerem, to consumers this summer. Ads from Chicago’s Cramer-Krasselt and AbelsonTaylor will start running in July. “We are absolutely committed to doing a broad-reaching, full-scale DTC campaign,” Tim Rudolphi, Takeda director of neuroscience marketing, told MM&M. Rozerem (ramelteon) was approved last August and hit pharmacy shelves the following month. AbelsonTaylor handled professional advertising from there, educating physicians about its unique mechanism of action and lack of abuse potential. With the DTC phase starting, Rudolphi said his company will spend considerably less than rivals Sepracor, which markets Lunesta (eszopiclone), and Sanofi-Aventis, which markets Ambien (zolpidem) and a controlled release version, Ambien CR. That could translate into less emphasis on mass-media venues than on targeted ones, although the campaign will include television, print, Web, direct mail and other channels, he said. A consumer Web site, rozerem.com, went live recently.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.